Trial · NCT04856917
Results by group321
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 321
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Facial Inflammatory Lesion Counts at Week 12 | Imsidolimab 400/200 mg | -6.8 | Standard Deviation 13.63 | lesions | |
| Change From Baseline in Facial Inflammatory Lesion Counts at Week 12 | Imsidolimab 200/100 mg | -7.4 | Standard Deviation 16.38 | lesions | |
| Change From Baseline in Facial Inflammatory Lesion Counts at Week 12 | Placebo | -9.6 | Standard Deviation 10.66 | lesions | |
| Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, and 20 | Imsidolimab 400/200 mg | Change at Week 2 | -1.9 | Standard Deviation 7.87 | lesions |
| Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, and 20 | Imsidolimab 200/100 mg | Change at Week 2 | -0.5 | Standard Deviation 7.30 | lesions |
| Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, and 20 | Placebo | Change at Week 2 | -3.8 | Standard Deviation 7.04 | lesions |
| Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, and 20 | Imsidolimab 400/200 mg | Change at Week 4 | -0.3 | Standard Deviation 15.21 | lesions |
| Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, and 20 | Imsidolimab 200/100 mg | Change at Week 4 | -4.4 | Standard Deviation 9.87 | lesions |
| Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, and 20 | Placebo | Change at Week 4 | -8.0 | Standard Deviation 9.64 | lesions |
| Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, and 20 | Imsidolimab 400/200 mg | Change at Week 8 | -5.5 | Standard Deviation 10.75 | lesions |
| Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, and 20 | Imsidolimab 200/100 mg | Change at Week 8 | -6.2 | Standard Deviation 12.43 | lesions |
| Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, and 20 | Placebo | Change at Week 8 | -7.8 | Standard Deviation 12.40 | lesions |
| Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, and 20 | Imsidolimab 400/200 mg | Change at Week 20 | -8.7 | Standard Deviation 11.42 | lesions |
| Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, and 20 | Imsidolimab 200/100 mg | Change at Week 20 | -12.0 | Standard Deviation 16.58 | lesions |
| Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, and 20 | Placebo | Change at Week 20 | -11.7 | Standard Deviation 9.00 | lesions |
| Percent Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, 12, and 20 | Imsidolimab 400/200 mg | Percent Change at Week 2 | -6.6 | Standard Deviation 27.87 | percent change |
| Percent Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, 12, and 20 | Imsidolimab 200/100 mg | Percent Change at Week 2 | -1.9 | Standard Deviation 27.37 | percent change |
| Percent Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, 12, and 20 | Placebo | Percent Change at Week 2 | -13.6 | Standard Deviation 25.76 | percent change |
| Percent Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, 12, and 20 | Imsidolimab 400/200 mg | Percent Change at Week 4 | -2.9 | Standard Deviation 44.00 | percent change |
| Percent Change From Baseline in Facial Inflammatory Lesion Counts at Weeks 2, 4, 8, 12, and 20 | Imsidolimab 200/100 mg | Percent Change at Week 4 | -14.1 | Standard Deviation 31.98 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04856917/results